Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Grifols, S.A. (GRFS)

11.99   0.09 (0.76%) 06-26 18:54
Open: 11.92 Pre. Close: 11.9
High: 12.01 Low: 11.82
Volume: 476,902 Market Cap: 11,291(M)
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 12.03 - 12.08 12.08 - 12.13
Low: 11.7 - 11.75 11.75 - 11.8
Close: 11.91 - 11.99 11.99 - 12.09

Technical analysis

as of: 2022-06-24 4:40:23 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 14.59     One year: 15.58
Support: Support1: 11.13    Support2: 9.26
Resistance: Resistance1: 12.49    Resistance2: 13.34
Pivot: 11.92
Moving Average: MA(5): 11.69     MA(20): 12.14
MA(100): 11.66     MA(250): 12.7
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 37.5     %D(3): 27.9
RSI: RSI(14): 48.7
52-week: High: 17.45  Low: 10.1
Average Vol(K): 3-Month: 867 (K)  10-Days: 652 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ GRFS ] has closed below upper band by 46.9%. Bollinger Bands are 16.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 24 Jun 2022
Grifols, S.A. (NASDAQ:GRFS) Shares Bought by Veriti Management LLC - Defense World

Thu, 23 Jun 2022
Queen's and PSAC 901 enter arbitration for research assistant job classifications - Queen's Journal

Thu, 23 Jun 2022
Grifols, S.A. (NASDAQ:GRFS) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World

Thu, 23 Jun 2022
Grifols, S.A. (NASDAQ:GRFS) Receives Average Rating of "Hold" from Brokerages - MarketBeat

Wed, 08 Jun 2022
Grifols Procleix Plasmodium Assay receives CE mark, a first for malaria blood screening - PR Newswire

Sun, 29 May 2022
Grifols, S.A. (NASDAQ:GRFS) Given Average Recommendation of "Hold" by Analysts - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. 688 (M)
Shares Float 834 (M)
% Held by Insiders 0 (%)
% Held by Institutions 42.9 (%)
Shares Short 5,940 (K)
Shares Short P.Month 4,810 (K)

Stock Financials

EPS 0.14
EPS Est Next Qtl 0.31
EPS Est This Year 1.21
EPS Est Next Year 1.34
Book Value (p.s.) 4.48
Profit Margin (%) 3.7
Operating Margin (%) 11.3
Return on Assets (ttm) 2
Return on Equity (ttm) 3.5
Qtrly Rev. Growth -8.5
Gross Profit (p.s.) 2.85
Sales Per Share 7.17
EBITDA (p.s.) 1.14
Qtrly Earnings Growth 0
Operating Cash Flow 597 (M)
Levered Free Cash Flow 64 (M)

Stock Valuations

PE Ratio 85.64
PEG Ratio 1.8
Price to Book value 2.67
Price to Sales 1.67
Price to Cash Flow 13.8

Stock Dividends

Dividend 0.46
Forward Dividend 0
Dividend Yield 3.8%
Dividend Pay Date 2021-06-13
Ex-Dividend Date 2021-06-02
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.